REGENERON PHARMACEUTICALS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Cash and Cash Equivalents, Period Increase (Decrease) of $240.80 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-07.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-07
- REGENERON PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $240.80M, a 16.44% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $379.89M, a 1740.73% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $169.97M, a 255.94% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$101.66M.
- REGENERON PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $655.00M, a 136.04% increase from fiscal 2017.
- REGENERON PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $277.50M.
- REGENERON PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$261.40M, a 262.98% decline from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $160.38M, a 41.79% increase from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2019-03-31 | $240.80M 10-Q · filed 2019-05-07 | $620.69M derived: sum of 2 quarters · filed 2019-05-07 | $790.66M derived: sum of 3 quarters · filed 2019-05-07 | $689.00M derived: sum of 4 quarters · filed 2019-05-07 | ||
| 2018-12-31 | $379.89M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $549.86M derived: sum of 2 quarters · filed 2019-02-07 | $448.20M derived: sum of 3 quarters · filed 2019-02-07 | $655.00M 10-K · filed 2019-02-07 | ||
| 2018-09-30 | $169.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $68.31M derived: sum of 2 quarters · filed 2018-11-06 | $275.11M 10-Q · filed 2018-11-06 | $295.75M derived: sum of 4 quarters · filed 2019-05-07 | ||
| 2018-06-30 | -$101.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $105.14M 10-Q · filed 2018-08-02 | $125.78M derived: sum of 3 quarters · filed 2019-05-07 | $173.53M derived: sum of 4 quarters · filed 2019-05-07 | ||
| 2018-03-31 | $206.80M 10-Q · filed 2019-05-07 | $206.76M 10-Q · filed 2018-05-03 | $227.44M derived: sum of 2 quarters · filed 2019-05-07 | $275.19M derived: sum of 3 quarters · filed 2019-05-07 | $207.73M derived: sum of 4 quarters · filed 2019-05-07 | |
| 2017-12-31 | $20.64M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $68.39M derived: sum of 2 quarters · filed 2019-02-07 | $930.00K derived: sum of 3 quarters · filed 2019-02-07 | $277.50M 10-K · filed 2019-02-07 | $277.53M 10-K · filed 2018-02-08 | |
| 2017-09-30 | $47.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$19.71M derived: sum of 2 quarters · filed 2018-11-06 | $256.86M 10-Q · filed 2018-11-06 | -$115.80M derived: sum of 4 quarters · filed 2019-02-07 | ||
| 2017-06-30 | -$67.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $209.11M 10-Q · filed 2018-08-02 | -$163.55M derived: sum of 3 quarters · filed 2019-02-07 | $110.30M derived: sum of 4 quarters · filed 2019-02-07 | ||
| 2017-03-31 | $276.57M 10-Q · filed 2018-05-03 | -$96.09M derived: sum of 2 quarters · filed 2019-02-07 | $177.76M derived: sum of 3 quarters · filed 2019-02-07 | $220.06M derived: sum of 4 quarters · filed 2019-02-07 | ||
| 2016-12-31 | -$372.66M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | -$98.81M derived: sum of 2 quarters · filed 2019-02-07 | -$56.51M derived: sum of 3 quarters · filed 2019-02-07 | -$261.40M 10-K · filed 2019-02-07 | -$273.90M 10-K · filed 2017-02-09 | |
| 2016-09-30 | $273.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $316.14M derived: sum of 2 quarters · filed 2017-11-08 | $111.26M 10-Q · filed 2017-11-08 | $265.77M derived: sum of 4 quarters · filed 2018-02-08 | ||
| 2016-06-30 | $42.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$162.59M 10-Q · filed 2017-08-03 | -$8.08M derived: sum of 3 quarters · filed 2018-02-08 | $255.95M derived: sum of 4 quarters · filed 2018-02-08 | ||
| 2016-03-31 | -$204.89M 10-Q · filed 2017-05-04 | -$50.37M derived: sum of 2 quarters · filed 2018-02-08 | $213.66M derived: sum of 3 quarters · filed 2018-02-08 | $96.31M derived: sum of 4 quarters · filed 2018-02-08 | ||
| 2015-12-31 | $154.51M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $418.55M derived: sum of 2 quarters · filed 2018-02-08 | $301.19M derived: sum of 3 quarters · filed 2018-02-08 | $160.38M 10-K · filed 2018-02-08 | ||
| 2015-09-30 | $264.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $146.68M derived: sum of 2 quarters · filed 2016-11-04 | $5.87M 10-Q · filed 2016-11-04 | $8.03M derived: sum of 4 quarters · filed 2017-02-09 | ||
| 2015-06-30 | -$117.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$258.17M 10-Q · filed 2016-08-04 | -$256.00M derived: sum of 3 quarters · filed 2017-02-09 | -$209.58M derived: sum of 4 quarters · filed 2017-02-09 | ||
| 2015-03-31 | -$140.81M 10-Q · filed 2016-05-05 | -$138.65M derived: sum of 2 quarters · filed 2017-02-09 | -$92.23M derived: sum of 3 quarters · filed 2017-02-09 | $46.05M derived: sum of 4 quarters · filed 2017-02-09 | ||
| 2014-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $48.58M derived: sum of 2 quarters · filed 2017-02-09 | $186.86M derived: sum of 3 quarters · filed 2017-02-09 | $113.11M 10-K · filed 2017-02-09 | ||
| 2014-09-30 | $46.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $184.70M derived: sum of 2 quarters · filed 2015-11-04 | $110.95M 10-Q · filed 2015-11-04 | $383.34M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2014-06-30 | $138.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $64.53M 10-Q · filed 2015-08-04 | $336.92M derived: sum of 3 quarters · filed 2016-02-11 | $218.46M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2014-03-31 | -$73.75M 10-Q · filed 2015-05-07 | $198.65M derived: sum of 2 quarters · filed 2016-02-11 | $80.18M derived: sum of 3 quarters · filed 2016-02-11 | $281.50M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2013-12-31 | $272.40M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $153.93M derived: sum of 2 quarters · filed 2016-02-11 | $355.25M derived: sum of 3 quarters · filed 2016-02-11 | $305.33M 10-K · filed 2016-02-11 | ||
| 2013-09-30 | -$118.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $82.85M derived: sum of 2 quarters · filed 2014-11-04 | $32.94M 10-Q · filed 2014-11-04 | $144.21M derived: sum of 4 quarters · filed 2015-02-12 | ||
| 2013-06-30 | $201.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $151.40M 10-Q · filed 2014-08-05 | $262.68M derived: sum of 3 quarters · filed 2015-02-12 | $209.73M derived: sum of 4 quarters · filed 2015-02-12 | ||
| 2013-03-31 | -$49.91M 10-Q · filed 2014-05-08 | $61.36M derived: sum of 2 quarters · filed 2015-02-12 | $8.42M derived: sum of 3 quarters · filed 2015-02-12 | -$214.22M derived: sum of 4 quarters · filed 2015-02-12 | ||
| 2012-12-31 | $111.28M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $58.33M derived: sum of 2 quarters · filed 2015-02-12 | -$164.31M derived: sum of 3 quarters · filed 2015-02-12 | -$253.33M 10-K · filed 2015-02-12 | ||
| 2012-09-30 | -$52.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | -$275.59M derived: sum of 2 quarters · filed 2013-11-05 | -$364.61M 10-Q · filed 2013-11-05 | -$87.40M derived: sum of 4 quarters · filed 2014-02-13 | ||
| 2012-06-30 | -$222.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$311.67M 10-Q · filed 2013-08-06 | -$34.45M derived: sum of 3 quarters · filed 2014-02-13 | -$82.37M derived: sum of 4 quarters · filed 2014-02-13 | ||
| 2012-03-31 | -$89.03M 10-Q · filed 2013-05-03 | $188.19M derived: sum of 2 quarters · filed 2014-02-13 | $140.27M derived: sum of 3 quarters · filed 2014-02-13 | $259.21M derived: sum of 4 quarters · filed 2014-02-13 | ||
| 2011-12-31 | $277.21M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $229.30M derived: sum of 2 quarters · filed 2014-02-13 | $348.23M derived: sum of 3 quarters · filed 2014-02-13 | $371.04M 10-K · filed 2014-02-13 | ||
| 2011-09-30 | -$47.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $71.02M derived: sum of 2 quarters · filed 2012-10-24 | $93.82M 10-Q · filed 2012-10-24 | -$118.89M derived: sum of 4 quarters · filed 2013-02-15 | ||
| 2011-06-30 | $118.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $141.74M 10-Q · filed 2012-07-25 | -$70.97M derived: sum of 3 quarters · filed 2013-02-15 | $142.31M derived: sum of 4 quarters · filed 2013-02-15 | ||
| 2011-03-31 | $22.80M 10-Q · filed 2012-04-26 | -$189.91M derived: sum of 2 quarters · filed 2013-02-15 | $23.38M derived: sum of 3 quarters · filed 2013-02-15 | $18.07M derived: sum of 4 quarters · filed 2013-02-15 | ||
| 2010-12-31 | -$212.71M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $572.00K derived: sum of 2 quarters · filed 2013-02-15 | -$4.74M derived: sum of 3 quarters · filed 2013-02-15 | -$94.50M 10-K · filed 2013-02-15 | ||
| 2010-09-30 | $213.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $207.97M derived: sum of 2 quarters · filed 2011-10-27 | $118.21M 10-Q · filed 2011-10-27 | $74.97M derived: sum of 4 quarters · filed 2012-02-21 | ||
| 2010-06-30 | -$5.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | -$95.08M 10-Q · filed 2011-07-28 | -$138.32M derived: sum of 3 quarters · filed 2012-02-21 | -$159.47M derived: sum of 4 quarters · filed 2012-02-21 | ||
| 2010-03-31 | -$89.76M 10-Q · filed 2011-05-03 | -$133.01M derived: sum of 2 quarters · filed 2012-02-21 | -$154.16M derived: sum of 3 quarters · filed 2012-02-21 | |||
| 2009-12-31 | -$43.25M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | -$64.39M derived: sum of 2 quarters · filed 2012-02-21 | -$40.72M 10-K · filed 2012-02-21 | |||
| 2009-09-30 | -$21.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $2.52M 10-Q · filed 2010-10-28 | ||||
| 2009-06-30 | $23.67M 10-Q · filed 2010-07-28 | |||||
| 2008-12-31 | -$251.13M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |